Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $7.45B
Last updated: Nov 17, 2026 at 11:05 AM ET
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) P/E Ratio & Valuation History
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) trades at 21.4x trailing earnings and 2.2x sales. Its P/E of 21.4x is above its 5-year median of 9.8x. Its forward P/E is 18.3x. The median P/E across 11 similar companies is 18.4x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 16.9% higher over the next year. Its free cash flow yield is 0.5%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 21.4x |
| Forward P/E | 18.3x |
| Price to sales | 2.2x |
| Price to book | 13.4x |
| EV/EBITDA | 15.3x |
| Price to FCF | 185.5x |
| EV/FCF | 264.1x |
| PEG | 2.0 |
| FCF yield | 0.5% |
Historical Medians
Against its 10-year medians, its P/E is 98.1% above 10.8x and its P/S is 450.0% above 0.4x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 21.4x | 9.8x | 10.8x |
| P/S | 2.2x | 0.5x | 0.4x |
Valuation History
Over the 10 year ends shown, its P/E ranged from 2.9x in 2022 to 26.4x in 2017.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $12.60 | 15.0x | 1.3x | N/A |
| 2024 | $7.92 | 13.7x | 0.9x | N/A |
| 2023 | $6.07 | 9.5x | 0.4x | 74.8x |
| 2022 | $1.99 | 2.9x | 0.1x | 1.0x |
| 2021 | $4.79 | 5.7x | 0.3x | 2.0x |
| 2020 | $4.57 | 7.3x | 0.3x | 2.2x |
| 2019 | $4.82 | 13.8x | 0.4x | 2.9x |
| 2018 | $13.53 | 13.7x | N/A | 1.9x |
| 2017 | $16.65 | 26.4x | 1.9x | N/A |
| 2016 | $13.25 | 11.3x | N/A | N/A |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About AMRX
What is AMRX's forward P/E ratio?
Amneal Pharmaceuticals, Inc. Class A Common Stock has a forward P/E ratio of 18.3x.
Is AMRX stock overvalued?
GNG's valuation label for AMRX is Overvalued. Its P/E of 21.4x compares with a median of 18.4x across 11 similar companies.
What is AMRX's price to sales ratio?
Amneal Pharmaceuticals, Inc. Class A Common Stock has a price to sales ratio of 2.2x.
What is Amneal Pharmaceuticals, Inc. Class A Common Stock's average P/E ratio over 5 years?
Amneal Pharmaceuticals, Inc. Class A Common Stock's median P/E over the last 5 years is 9.8x, from 60 month-end values through Oct 2026.
What is AMRX's PEG ratio?
Amneal Pharmaceuticals, Inc. Class A Common Stock has a PEG ratio of 2.0.
AMRX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors